- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | -5,49 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ARGENX | 688,00 | -0,03 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Argenx nach Eckdaten für 2025 auf "Hold" mit einem Kursziel von 675 Euro belassen. Der Umsatz mit dem Medikament Vyvgart... ► Artikel lesen | |
| ORAGENICS | 0,750 | +17,98 % | Oragenics, Inc.: Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program | ||
| LEXICON PHARMACEUTICALS | 1,085 | +4,63 % | Lexicon Pharmaceuticals schließt Kapitalerhöhung über 100 Millionen US-Dollar ab | ||
| OUTLOOK THERAPEUTICS | 0,377 | +3,34 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development | ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,535 | -1,83 % | CSTONE PHARMA-B (02616): UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE | ||
| KRYSTAL BIOTECH | 230,10 | 0,00 % | Krystal Biotech, Inc.: Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis | Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,281 | 0,00 % | GenScript USA: 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week | PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech... ► Artikel lesen | |
| SERES THERAPEUTICS | 11,080 | -4,65 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 5,400 | -12,90 % | Aligos Therapeutics, Inc. - 8-K, Current Report | ||
| Q32 BIO | 3,680 | +2,22 % | Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected... ► Artikel lesen | |
| XENETIC BIOSCIENCES | 2,090 | +0,48 % | Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting | Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.